Pharma
In 2021, a team led by neurosurgeon and engineer Ben Rapoport embarked on an ambitious journey to bridge the gap between artificial intelligence and human thought. Precision Neuroscience was born with a clear focus: improving the lives of people with severe neurological conditions through brain-computer interfaces (BCI). Less than three years later, the company has now raised a $102 million Series C round, marking a critical milestone in its mission and positioning itself firmly alongside, if not against, Elon Musk’s Neuralink.
The latest round, led by General Equity Holdings, comes with notable participation from Steadview Capital, B Capital, and the Duquesne Family Office, headed by prominent investor Stanley Druckenmiller. With this funding, Precision Neuroscience’s total capital raised now stands at $155 million. The deal also follows a recently secured $93 million from a planned $100 million round just months prior—valuing the startup at approximately $500 million.
While brain implants are not new to neuroscience, recent breakthroughs in AI and hardware design have breathed new life into the field. Precision’s flagship device, the Layer 7 Cortical Interface, is central to this momentum. Measuring just a fifth the thickness of a human eyelash, this flexible, wafer-thin film is designed to conform to the brain's surface and relay signals directly to a connected device. This relatively non-invasive implant works by capturing brain signals through thin-film electrodes, processing the data with a local unit placed between the skull and scalp, and then translating those signals into actions on digital devices.
